ImmuLogic Restructures Board Of Directors
WALTHAM, Mass., March 5 /PRNewswire/ -- Immulogic Pharmaceutical Corp today reported a restructuring of
its Board of Directors. Five new members have been appointed to the eight person Board of Directors, effective
immediately. They are J. Joseph Marr, M.D. acting President and Chief Executive Officer of ImmuLogic; C.
Garrison Fathman, M.D., Professor, Department of Medicine, Stanford University School of Medicine; Carl
Goldfischer, M.D., Chief Financial Officer, Vice President Finance and Strategic Planning, of ImClone Systems
Inc.; Geraldine Henwood, Chief Executive Officer of IBAH, Inc.; and Richard Pops, Chief Executive Officer of
Alkermes Inc. These appointments follow the resignation of Malcolm Gefter, Ph.D., Chairman of the Board and
scientific founder, Alan Dalby, Howard Jacobson, Kenneth Melmon, M.D., and Larry Soll, Ph.D. Two individuals,
appointed to the Board in September 1996, will continue as Directors, they are Samuel Fleming, Chairman and Chief
Executive Officer of Decision Resources, Inc. and Paul Friedman, M.D., President of Dupont Merck Research Labs.
"This restructuring was done in consultation with several major stockholders with the purpose of adding
pharmaceutical and business advisory capabilities to the Board. The newly constituted Board has the diversity of
talent and experience needed to guide ImmuLogic at its present stage of development," said Dr. Joseph Marr, acting
President and Chief Executive Officer. "We thank the Board members who are stepping down for their contributions
to the company over the last several years. We would like especially to acknowledge Dr. Malcolm Gefter for his
scientific and business contributions since he founded the Company in 1987."
The Company has entered into a severance agreement with Dr. Gefter providing for payments commensurate with
those otherwise due under his employment contract.
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company, located in Waltham, Masschusetts,
specializing in the development of peptide immunotherapeutics, with a primary focus on allergies, including cat and
ragweed allergies, and autoimmune diseases such as multiple sclerosis. The company also is developing a cocaine
vaccine. The company's press releases are available through Company News on Call by fax at 800-758-5804, ext.
114501, and on the Internet at www.prnewswire.com. SOURCE ImmuLogic Pharmaceutical Corporation |
